Therapeutic Antibodies + Cytokines p.117-118 Flashcards
Alemtuzumab
Target: CD52
Tx: CLL, MS
Bevacizumab
Target: VEGF
Tx: Colorectal Cancer, Renal Cell Carcinoma, Non-Small Cell Lung Cancer
Cetuximab
Target: EGFR
Tx: Stage IV Colorectal Cancer, Head and Neck Cancer
Rituximab
Target: CD20
Tx: B-Cell non-Hodgkin Lymphoma, CLL, Rheumatoid Arthritis, ITP
Trastuzumab
Target: HER2/neu
Tx: Breast Cancer, Gastric Cancer
Adamlimumab
Target: Soluble TNF-alpha
Tx: IBD, Rheumatoid arthritis, Ankylosing spondylitis, Psoriasis
Certolizumab
Target: Soluble TNF-alpha
Tx: IBD, Rheumatoid arthritis, Ankylosing spondylitis, Psoriasis
Golimumab
Target: Soluble TNF-alpha
Tx: IBD, Rheumatoid arthritis, Ankylosing spondylitis, Psoriasis
Infliximab
Target: Soluble TNF-alpha
Tx: IBD, Rheumatoid arthritis, Ankylosing spondylitis, Psoriasis
Etanercept
Not actually a monoclonal antibody.
Acts as a TNF-alpha receptor decoy
Daclizumab
Target: CD25 (part of IL-2 receptor)
Tx: Relapsing MS
Eculizumab
Target: Complement Protein C5
Tx: Paroxysmal Nocturnal Hemoglobinuria
Natalizumab
Target: a4-integrin
Tx: MS, Crohn DIsease
Risk of PML in patients with JC virus
Ustekinumab
Target: IL-12/IL-23
Tx: Psoriasis, Psoriatic Arthritis
Abciximab
Platelet Glycoproteins IIb/IIIa
Tx: Antiplatelet for patients undergoing PCI
Denosumab
Target: RANKL
Tx: Osteoporosis, Inhibits osteoclast maturation (mimics Osteoprotegrin)
Digoxin Immune Fab
Antidote for Digoxin Toxicity
Omalizumab
Target: IgE
Tx: Refractory Allergic Asthma
Prevents IgE binding to FceRI
Palivizumab
Target: RSV F Protein
Tx: RSV Prophylaxis for high-risk infants
Ranibizumab
Bevacizumab
Target: VEGF
Tx: Neovascular age-related macular degeneration
Proliferative Diabetic Retinopathy
Macular Edema
Aldesleukin (IL-2)
Renal Cell Carcinoma
Metastatic Melanoma
Epoetin alfa
Anemias (esp in Renal failure)
Filgrastim (G-CSF)
Recovery of bone marrow and WBC counts by GRANULOCYTE stimulation
Sargramostim (GM-CSF)
Recovery of bone marrow and WBC counts by GRANulocyte and MONocyte stimulation
